Bordeaux PharmacoEpi, INSERM CIC1401, Université de Bordeaux, Bordeaux, France.
INSERM U1219, Université de Bordeaux, Bordeaux, France.
Pharmacoepidemiol Drug Saf. 2020 Sep;29(9):993-1000. doi: 10.1002/pds.4983. Epub 2020 Mar 4.
To introduce the methodology of the ALCAPONE project.
The French National Healthcare System Database (SNDS), covering 99% of the French population, provides a potentially valuable opportunity for drug safety alert generation. ALCAPONE aimed to assess empirically in the SNDS case-based designs for alert generation related to four health outcomes of interest.
ALCAPONE used a reference set adapted from observational medical outcomes partnership (OMOP) and Exploring and Understanding Adverse Drug Reactions (EU-ADR) project, with four outcomes-acute liver injury (ALI), myocardial infarction (MI), acute kidney injury (AKI), and upper gastrointestinal bleeding (UGIB)-and positive and negative drug controls. ALCAPONE consisted of four main phases: (1) data preparation to fit the OMOP Common Data Model and select the drug controls; (2) detection of the selected controls via three case-based designs: case-population, case-control, and self-controlled case series, including design variants (varying risk window, adjustment strategy, etc.); (3) comparison of design variant performance (area under the ROC curve, mean square error, etc.); and (4) selection of the optimal design variants and their calibration for each outcome.
Over 2009-2014, 5225 cases of ALI, 354 109 MI, 12 633 AKI, and 156 057 UGIB were identified using specific definitions. The number of detectable drugs ranged from 61 for MI to 25 for ALI. Design variants generated more than 50 000 points estimates. Results by outcome will be published in forthcoming papers.
ALCAPONE has shown the interest of the empirical assessment of pharmacoepidemiological approaches for drug safety alert generation and may encourage other researchers to do the same in other databases.
介绍 ALCAPONE 项目的方法学。
法国国家医疗保健系统数据库(SNDS)覆盖了 99%的法国人口,为生成药物安全性警报提供了一个潜在有价值的机会。ALCAPONE 旨在通过 SNDS 中的基于案例的设计,对与四个感兴趣的健康结果相关的警报生成进行实证评估。
ALCAPONE 使用了从观察性医疗结果合作(OMOP)和探索和理解药物不良反应(EU-ADR)项目改编的参考集,有四个结果——急性肝损伤(ALI)、心肌梗死(MI)、急性肾损伤(AKI)和上消化道出血(UGIB)——以及阳性和阴性药物对照。ALCAPONE 由四个主要阶段组成:(1)数据准备以适应 OMOP 通用数据模型并选择药物对照;(2)通过三种基于案例的设计(病例人群、病例对照和自控制病例系列,包括设计变体(改变风险窗口、调整策略等))检测选定的对照;(3)比较设计变体的性能(ROC 曲线下面积、均方误差等);(4)选择最佳设计变体及其对每个结果的校准。
在 2009 年至 2014 年期间,使用特定定义,确定了 5225 例 ALI、354109 例 MI、12633 例 AKI 和 156057 例 UGIB 病例。可检测药物的数量从 MI 的 61 种到 ALI 的 25 种不等。设计变体生成了超过 50000 个点估计值。结果将在即将发表的论文中公布。
ALCAPONE 已经表明了对药物安全性警报生成的药物流行病学方法的实证评估的兴趣,并且可能鼓励其他研究人员在其他数据库中进行相同的研究。